The Sjogren's Syndrome Damage Index--a damage index for use in clinical trials and observational studies in primary Sjogren's syndrome

Barry, Robert J.; Sutcliffe, Nurhan; Isenberg, David; Price, Elizabeth; Goldblatt, Fiona; Adler, Margaret; Canavan, A.; Hamburger, J; Richards, Andrea; Regan, Marian; Gadsby, K.; Rigby, S.; Jones, Adrian; Mathew, Ricky; Mulherin, D.; Stevenson, A. C.; Nightingale, Peter; Rauz, Saaeha; Bowman, Simon

doi:10.1093/rheumatology/ken164

Cited by 50 publications

(28 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Primary SS activity was measured by means of the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI), which includes 12 domains: constitutional, lymphadenopathy, glandular, articular, cutaneous, pulmonary, renal, muscular, peripheral nervous system, central nervous system, hematologic, and biologic (23). Conversely, the accumulated irreversible damage in primary SS was evaluated by means of the Sjögren's Syndrome Damage Index (SSDI), which comprises the following domains: ocular, oral, and systemic (neurologic, renal, pulmonary, cardiovascular, gastrointestinal, musculoskeletal, endocrine, and malignancy) damage (24).…”

Section: Methodsmentioning

confidence: 99%

Prevalence of and Factors Associated With Increased Arterial Stiffness in Patients With Primary Sjögren's Syndrome

Sabio

Sánchez-Berná

Martínez-Bordonado

et al. 2015

Arthritis Care & Research

View full text Add to dashboard Cite

Objective. To compare the presence of subclinical atherosclerosis measured by means of pulse wave velocity (PWV) in women with primary Sjögren's syndrome (SS) versus a healthy age-and sex-matched control group, and to identify factors independently associated with PWV in primary SS. Methods. Forty-four women with primary SS and 78 age-matched healthy women without overt cardiovascular (CV) diseases were assessed for traditional and nontraditional CV risk factors. PWV was also performed. A linear regression analysis was used to identify factors independently associated with PWV in primary SS. Results. Women with primary SS had significantly higher PWV than controls (P ‫؍‬ 0.030), and the frequency of increased PWV was significantly higher in this group (25% versus 8%; P ‫؍‬ 0.013). The proportion of patients ages <50 years (ratio 4.6) with increased PWV was almost 2-fold higher than those ages >50 years (ratio 2.4) with respect to controls. Positivity for anti-SSB was more frequent in patients with normal PWV than in those with increased PWV (61% versus 18%; P ‫؍‬

show abstract

Section: Methodsmentioning

confidence: 99%

Prevalence of and Factors Associated With Increased Arterial Stiffness in Patients With Primary Sjögren's Syndrome

Sabio

Sánchez-Berná

Martínez-Bordonado

et al. 2015

Arthritis Care & Research

View full text Add to dashboard Cite

show abstract

“…The scores were converted to a numeric variable according to the authors' recommendations ( Table 1). We also used a modified version of the SCAI (9), in which subjective features such as fatigue, myalgia, arthralgia, Raynaud's phenomenon, shortness of breath, and pleuropericardial pain are excluded.…”

Section: Abstraction and Standardization Of Patient Profilesmentioning

confidence: 99%

Accurate detection of changes in disease activity in primary Sjögren's syndrome by the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index

Séror

Mariette

Bowman

et al. 2010

Arthritis Care & Research

View full text Add to dashboard Cite

Objective. To assess and compare the sensitivity to change of the European League Against Rheumatism Sjö gren's Syndrome Disease Activity Index (ESSDAI) with that of other primary Sjö gren's syndrome (SS) disease activity indexes. Methods. We abstracted 96 patient profiles, including data on 3 successive visits (visits 1-3), from the medical charts of patients with primary SS. Patient profiles were scored with the ESSDAI, SS Disease Activity Index (SSDAI), and Sjö gren's Systemic Clinical Activity Index (SCAI). Thirty-nine experts assessed 5 profiles for whether disease activity had improved, worsened, or remained stable at visits 2 and 3. Results. For improved patients, the standardized response means (SRMs) for all scores did not differ, and ranged from ؊1.08 to ؊1.38 between visits 1 and 2 and from ؊0.50 to ؊0.76 between visits 2 and 3. For patients with worsened activity, the SRMs between visits 1 and 2 and between visits 2 and 3 were ؉0.46 and ؉1.10 for the ESSDAI, ؊0.03 and ؉0.79 for the SSDAI, and ؉0.17 and ؉1.02 for the SCAI, respectively. For patients with stable activity, the SRMs between visits 1 and 2 and between visits 2 and 3 were 0.00 and ؊0.13 for the ESSDAI, ؊0.44 and ؊0.11 for the SSDAI, and ؊0.36 and ؉0.34 for the SCAI, respectively. Conclusion. For patients with improved activity, the 3 disease activity indexes showed similar, large sensitivity to change. However, the ESSDAI seemed to detect changes in activity more accurately than other disease activity indexes. Notably, for patients with stable activity, the ESSDAI did not show erroneous improvement.

show abstract

“…The association between MPV and rheumatic diseases, such as systemic sclerosis (2), familial Mediterranean fever (3), rheumatoid arthritis (4), ankylosing spondylitis (5) and Behçet's disease (6) has been previously reported. In Sjögren's syndrome (SS), acute phase reactants are not included in the activity indexes, such as Sjögren's syndrome disease activity index (SSDAI) and Sjögren's systemic clinical activity index (7,8). Therefore, reliable parameters correlating with disease activity are needed.…”

Section: Letter To the Editormentioning

confidence: 99%

“…Forty-two patients with primary SS (PSS), diagnosed according to the 2012 American College of Rheumatology Sjögren Classification Criteria (9), and 32 healthy volunteers were enrolled. SSDAI was used to determine SS activity (7). The study protocol was approved by the Local Research Ethical Committee.…”

Section: Letter To the Editormentioning

confidence: 99%

Sjögren’s syndrome and mean platelet volume

et al. 2015

View full text Add to dashboard Cite

show abstract

The Sjogren's Syndrome Damage Index--a damage index for use in clinical trials and observational studies in primary Sjogren's syndrome

Abstract: This study begins validation of a tool for collection of longitudinal damage data in PSS. We recommend further trial in both the experimental and clinical environment.

Cited by 50 publications

References 12 publications

Prevalence of and Factors Associated With Increased Arterial Stiffness in Patients With Primary Sjögren's Syndrome

Prevalence of and Factors Associated With Increased Arterial Stiffness in Patients With Primary Sjögren's Syndrome

Accurate detection of changes in disease activity in primary Sjögren's syndrome by the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index

Sjögren’s syndrome and mean platelet volume

Contact Info

Product

Resources

About